Esperion Therapeutis.Inc. buy Cantor Fitzgerald
Start price
17.12.24
/
50%
€2.41
Target price
17.12.25
€7.61
Performance (%)
41.71%
Price
22:26
€3.41
Summary
This prediction is currently active. With a performance of 41.71% the BUY prediction by Cantor_Fitzgerald is a big success. This prediction currently runs until 17.12.25. The prediction end date can be changed by Cantor_Fitzgerald at any time. Cantor_Fitzgerald has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Esperion Therapeutis.Inc. | 32.003% | 32.003% |
| iShares Core DAX® | 3.608% | -2.170% |
| iShares Nasdaq 100 | 4.362% | -1.854% |
| iShares Nikkei 225® | 3.371% | -2.409% |
| iShares S&P 500 | 3.596% | -0.427% |
Comments by Cantor_Fitzgerald for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
Esperion Therapeutics, Inc. (NASDAQ: ESPR) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $8.00 price target on the stock.
Ratings data for ESPR provided by MarketBeat